ACI-812

N/A

Report date: 2025/06/11 20:01:15

NME

Base Information

Drug NameACI-812

Drug Alias NameMorphomersamyloid-beta oligomer aggregation inhibitor (AC Immune)Beta amyloid beta sheet formation inhibitor (AC Immune)beta-amyloid oligomer inhibitors (AC Immune)ACI-140 +[8]

ClassificationSmall molecules

Mechanisms of ActionSynuclein alpha inhibitorsNeuroprotectantsBeta amyloid A4 protein aggregation inhibitors

TargetsBeta amyloid A4 proteinSynuclein alpha

Therapy Area/IndicationsAlzheimer DiseaseParkinson Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySwitzerland

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesAc Immune Sa

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAc Immune Sa

Active IndicationsN/A

Inactive IndicationsAlzheimer DiseaseParkinson Disease

Other Information

ATC CodeN/A